NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

Novocure's stock rockets into record territory after upbeat DMC review of lung cancer treatment trial

Shares of Novocure Ltd. NVCR, 1.25% skyrocketed 80.7% toward a record high in premarket trading Tuesday, after the tumor treatment company said an independent data monitoring committee (DMC) said the interim analysis of a Phase 3 trial would be accelerated. The trial is of Novocure's Tumor Treating Fields, which are electric fields that disrupt cancer cell division, in stage 4 non-small cell lung cancer. The DMC concluded that the trail should continue with no evidence of increased systemic toxicity. Novocure plans to submit an Investigational Device Exemption (IDE) to the Food and Drug Administration. "The accelerated interim analysis with an encouraging outcome adds to the accumulating evidence of Tumor Treating Fields' broad potential across a range of hard-to-treat cancers," said Novocure Executive Chairman William Doyle. Novocure's stock, which is on track to open well above its Feb. 19 record close of $190.17, has dropped 25.5% over the past three months through Monday while the S&P 500 SPX, -0.19% has gained 8.4%.

https://www.marketwatch.com/story/novocures-stock-rockets-into-record-territory-after-upbeat-dmc-review-of-lung-cancer-treatment-trial-2021-04-13